Evaluating haemodynamic changes: vericiguat in patients with heart failure with reduced ejection fraction

Key Points

• Vericiguat showed significant haemodynamic changes in heart failure with reduced ejection fraction patients, indicating its effectiveness.
• The primary metric evaluated was the impact on ejection fraction in patients with worsening heart failure.
• Assessment focused on vericiguat's haemodynamic effects compared to standard therapies across participant groups in clinical settings for heart failure treatment.  The findings suggest the need for more comprehensive studies to better understand the full potential of the drug.